|
|
|
| Relationship between Levels of Serum Hmga1 CK19 and CA125 and the Severity of Cervical Cancer |
| KANG Yongjun, LI Min, ZHANG Xiaohui, et al |
| The First Affiliated Hospital of Anhui Medical University,Anhui Hefei 230022, China |
|
|
|
|
Abstract Objective: To study the relationship between levels of serum high mobility proteina1 (Hmga1), cytokeratin (CK) 19 and carbohydrate antigen (CA) 125 and the severity of cervical cancer to provide bases for clinical diagnosis and evaluation of the condition. Methods: The clinical data of 70 patients with cervical cancer (cervical cancer group) diagnosed in the hospital from January 2019 to June 2019 were retrospectively analyzed. The clinical data of 40 patients with cervical intraepithelial neoplasia (CIN) (precancerous lesion group) discovered during gynecologic tumor screening and 30 healthy women (control group) were collected for comparison. The levels of hmga1, CK19 and CA125 in serum of the three groups were compared, and their relationship with the severity of cervical cancer was analyzed. Results: The levels of hmga1, CK19 and CA125 in serum showed cervical cancer grouP> precancerous lesion grouP> control group (P<0.05). In cervical cancer group, there were no significant differences in levels of serum hmga1, CK19 or CA125 between patients with different tumor diameters and pathological types (P>0.05), while levels of serum hmga1, CK19 and CA125 were significantly higher in stage III~IV than in stage I~II, significantly higher in patients with moderate and poor differentiation than in patients with high differentiation, and significantly higher in patients with lymph node metastasis than in patients without (P<0.05). Conclusion: The levels of hmga1, CK19 and CA125 in serum of patients with cervical cancer are significantly increased, and are closely related to stage, differentiation and metastasis. They can be used as auxiliary means for clinical diagnosis of cervical cancer and assessment of the severity of the disease.
|
|
|
|
|
|
[1] 龚静,张军.《2016年NCCN宫颈癌临床实践指南》解读[J].中国全科医学,2016,19(27):3261~3264.
[2] FeoliF,RenardC,AbouyahiaM,et al.Retrospective rescreening of negative cervical cytology samples preceding histologically proven CIN2-3 and squamous cell carcinoma:an educational opportunity to understand and prevent laboratory errors[J].Acta Cytologica,2015,59(3):265.
[3] 周锐,董慧明,丁淑琴,等.HMGA1在乳腺癌中的表达及临床意义[J].安徽医科大学学报,2017,52(11):1690~1693.
[4] Meva J,Chaudhary RK,Bhaduri D,et al.Lacunae in international federation of gynecology and obstetrics(FIGO)classification for cervical carcinoma:observational study using TNM classification as comparator.[J].Int Gynecol Cancer,2013,23(6):1071.
[5] 陈东真.妇产科诊断病理学[M].北京:人民军医出版社,2010.118~25.
[6] 林胜,王卫.CK20、HMGB1蛋白在宫颈鳞癌组织中的表达水平及临床意义[J].标记免疫分析与临床,2017,24(8):917~920.
[7] 张洋,董理,孙源博,等.下调HMGA1对乳腺癌MCF7细胞增殖和侵袭能力的影响及机制[J].山东医药,2017,57(38):15~18.
[8] 苏光,唐振利,张凡,等.HPVL1蛋白和HMGA1在子宫颈病变中的表达及临床意义[J].中国妇产科临床杂志,2016,17(4):319~322.
[9] Akhter M Z,LuthraK,Rajeswari M R.Molecular aspects on adriamycin interaction with hmga1 regulatory region and its inhibitory effect on HMGA1 expression in human cervical cancer[J].Journal of Biomolecular Structure&Dynamics,2015,34(4):877~891.
[10] 谭文福,吴绪峰.宫颈癌患者血清中hmga1和CK19蛋白的表达及其临床意义[J].实用癌症杂志,2017,32(3):361~363.
[11] 李英,刘坤,杨瀚.血清SCC-Ag、CK19水平变化与宫颈癌患者淋巴结转移的关联性分析[J].实验与检验医学,2018,36(6):950~952.
[12] 杨琳琳,王薇,张磊,等.宫颈癌患者治疗前检测血清HPV16E6 mRNA和CK19 mRNA的临床意义[J].昆明医科大学学报,2017,38(1):23~26.
[13] 郁平,姬小凡,王敏,等.MRI、血清CA125及HE4对卵巢癌的诊断价值分析[J].中国CT和MRI杂志,2019,17(12):97~99.
[14] 张蕾,曾凡清.血清中SCC-Ag、CEA和CA125联合检测在宫颈癌诊断中的意义[J].中国实验诊断学,2017,21(10):1708~1710.
[15] 王金华,郑秀,陈丽红,等.血清鳞癌相关抗原、糖类抗原125表达与宫颈癌临床分期的相关性[J].中国临床药理学杂志,2015,31(15):1546~1548. |
|
|
|
2020, Vol. 26 
